Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
19.96
+1.02 (5.39%)
Nov 26, 2025, 4:00 PM EST - Market closed
Theravance Biopharma Revenue
Theravance Biopharma had revenue of $19.99M in the quarter ending September 30, 2025, with 18.51% growth. This brings the company's revenue in the last twelve months to $80.33M, up 27.12% year-over-year. In the year 2024, Theravance Biopharma had annual revenue of $64.38M with 12.12% growth.
Revenue (ttm)
$80.33M
Revenue Growth
+27.12%
P/S Ratio
12.41
Revenue / Employee
$828,113
Employees
97
Market Cap
1.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64.38M | 6.96M | 12.12% |
| Dec 31, 2023 | 57.42M | 6.08M | 11.84% |
| Dec 31, 2022 | 51.35M | -3.97M | -7.17% |
| Dec 31, 2021 | 55.31M | -16.55M | -23.03% |
| Dec 31, 2020 | 71.86M | -1.56M | -2.12% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TBPH News
- 6 days ago - Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 - PRNewsWire
- 8 days ago - Theravance Biopharma to Participate in Upcoming Investor Conferences - PRNewsWire
- 15 days ago - Here's Why Shares in Theravance Biopharma Exploded Today - The Motley Fool
- 16 days ago - Theravance Biopharma, Inc. (TBPH) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 4 weeks ago - Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System - PRNewsWire
- 4 weeks ago - Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 - PRNewsWire
- 6 weeks ago - Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy - Business Wire